@1decentralizedd@BioValues They said last earnings call expected “in the third quarter of 2026.” September 30 is simply the last day of calendar Q3.
In Bolt's May 12, 2026 Q1 results, CEO Willie Quinn said:
“we look forward to reporting initial data in the third quarter of 2026.”
@WePickYouWin1@BioValues That is a slight de risking event as that was one of the main issues with BDC-1001 however it doesn’t tell us the medication is working to revert the cancer.
@1decentralizedd@BioValues Bolt's CEO said they saw a “clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated.”
That's meaningful because Bolt's original ISAC program, BDC-1001, ultimately wasn't good enough.
@BioValues Sounds Like $BOLT data will be decent, CEO reference it on last earnings call, plus they’ve consolidated drug development behind this one drug
@BioValues Sounds Like $BOLT data will be decent, CEO reference it on last earnings call, plus they’ve consolidated drug development behind this one drug
@MicrobotMedical $MBOT
You've indicated a future LIBERTY version is expected for neurovascular procedures. Can you discuss the development timeline, technical differences from the current system, and how this fits into your commercialization strategy?
Nice call by @SHYROSHIALPHA, everyone in crypto should be supporting the dev and content creator @GreenManReports behind $UNCKITA, he locked his own tokens, and building organically.
CA: 31ZBpTjfC9Lj9WFxQdjTigphLpdMpkk91SzKRPhMpump